Stammdaten
Mirum Pharmaceuticals, Inc., ein Biopharmaunternehmen, konzentriert sich auf die Entwicklung und Kommerzialisierung neuartiger Therapien für schwächende seltene und Orphan-Krankheiten. Der Hauptproduktkandidat des Unternehmens ist LIVMARLI, ein experimentelles Oral-Arzneimittel zur Behandlung der progressiven familiären intrahepatischen Cholestase-Krankheit sowie zur Behandlung des Alagille-Syndroms und der Gallengangsatresie-Krankheit. Das Unternehmen entwickelt auch das Arzneimittel Volixibat zur Behandlung der intrahepatischen Cholestase in der Schwangerschaft und der primären sklerosierenden Cholangitis. Mirum Pharmaceuticals, Inc. wurde 2018 gegründet und hat seinen Sitz in Foster City, Kalifornien. KI
Unternehmen & Branche
| Name | Mirum Pharmaceuticals, Inc. |
|---|---|
| Ticker | MIRM |
| CIK | 0001759425 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Pharmazeutische Erzeugnisse |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 604749101 |
|---|---|
| ISIN | US6047491013 |
| Typ | Common Stock |
| Marktkapitalisierung | 5,87 Mrd. USD |
| Beta | 0,52 |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 989 EAST HILLSDALE BOULEVARD, SUITE 300, 94404 FOSTER CITY, CA |
| Telefon | 650-667-4085 |
| EIN (IRS) | 83-1281555 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
Bewertung
| KBV (P/B) | 18,64 vs. 4,06 (2021) ▲ |
|---|---|
| KUV (P/S) | 11,25 vs. 25,49 (2021) ▼ |
| EV/EBITDA | 2.646,5 |
| FCF-Rendite | 0,9 % vs. -27,2 % (2021) ▲ |
Qualität & Bilanz
| Operative Marge | -4,2 % vs. -906,1 % (2021) ▲ |
|---|---|
| Nettomarge | -4,5 % vs. -438,9 % (2021) ▲ |
| ROIC | -7,2 % vs. -68,4 % (2021) ▲ |
| Nettoverschuldung/EBITDA | -136,2 |
| Zinsdeckungsgrad | -1,5 |
| Forderungslaufzeit (DSO) | 86 T vs. 62 T (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 4,06 | 5,07 | 5,55 | 8,86 | 13,03 | 24,19 | |
| KUV (P/S) | 25,49 | 9,35 | 7,40 | 5,93 | 7,86 | 10,30 | |
| FCF-Rendite | -27,2 % | -16,7 % | -5,2 % | 0,5 % | 1,3 % | -2,9 % | |
| Qualität & Bilanz | |||||||
| Operative Marge | -906,1 % | -170,3 % | -58,6 % | -26,0 % | -4,2 % | -139,8 % | |
| Nettomarge | -438,9 % | -176,0 % | -87,7 % | -26,1 % | -4,5 % | -140,2 % | |
| ROIC | -68,4 % | -94,1 % | -65,3 % | -37,4 % | -7,2 % | -312,0 % | |
| Zinsdeckungsgrad | – | -8,2 | -7,2 | -6,1 | -1,5 | -55,3 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
MIRM
Mirum Pharmaceuticals, Inc.
Effektiv
Neutral
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
81,1
64 neu, 124 erhöht, 1320,5M $ netto
Aktivist
0,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 108.70 | +5.1 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 91.77 | +24.4 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 116.41 | EMA50: 111.13 | |
| MACD-Histogramm | Bärisch | 10 % | -1.755 | Bearisch | |
| RSI(14) | Neutral | 10 % | 48.1 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 22.0 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 21.5 | +DI: 17.3 / −DI: 23.4 | |
| Z-Score(60) | Neutral | 5 % | 0.57 | In Range | |
| 52W-Position | Bullisch | 5 % | 81.4 % | Hoch 128.57 / Tief 51.12 | |
| Bollinger(20,2σ) | Bullisch | 5 % | 18.5 % | Upper 129.40 / Mid 120.08 / Lower 110.76 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.4129 | R²=0.44 / annualisiert +96.3 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-06 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -300 | 124,94 | -37.482,00 | -4,5% | |
| 2026-07-06 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -4.181 | 122,34 | -511.503,54 | -61,4% | |
| 2026-07-06 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -12.134 | 121,65 | -1.476.101,10 | -177,2% | |
| 2026-07-06 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -1.975 | 123,74 | -244.386,50 | -29,3% | |
| 2026-07-06 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -1.710 | 124,79 | -213.390,90 | -25,6% | |
| 2026-07-06 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3.124 | 121,67 | -380.097,08 | -45,6% | |
| 2026-07-06 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.048 | 122,43 | -128.306,64 | -15,4% | |
| 2026-07-06 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -528 | 123,84 | -65.387,52 | -7,9% | |
| 2026-07-01 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -2.721 | 120,00 | -326.520,00 | -39,2% | |
| 2026-06-17 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -2.594 | 101,95 | -264.458,30 | -31,8% | |
| 2026-06-08 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.567 | 95,12 | -149.053,04 | -17,9% | |
| 2026-06-08 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -2.258 | 92,84 | -209.632,72 | -25,2% | |
| 2026-06-08 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.175 | 93,95 | -110.391,25 | -13,3% | |
| 2026-06-01 | Ramasastry Saira | Director | Open Market Sale | -3.977 | 100,00 | -397.700,00 | -47,8% | |
| 2026-06-01 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -16.595 | 95,34 | -1.582.167,30 | -190,0% | |
| 2026-06-01 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -6.926 | 96,15 | -665.934,90 | -80,0% | |
| 2026-06-01 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -2.602 | 94,64 | -246.253,28 | -29,6% | |
| 2026-06-01 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -1.973 | 97,56 | -192.485,88 | -23,1% | |
| 2026-06-01 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -1.021 | 98,20 | -100.262,20 | -12,0% | |
| 2026-06-01 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -883 | 99,66 | -87.999,78 | -10,6% | |
| 2026-04-15 | Ramasastry Saira | Director | Open Market Sale | -2.000 | 96,90 | -193.800,00 | -23,3% | |
| 2026-03-16 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -40.985 | 91,98 | -3.769.714,23 | -452,7% | |
| 2026-03-16 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -4.732 | 91,98 | -435.239,42 | -52,3% | |
| 2026-03-16 | Ramasastry Saira | Director | Open Market Sale | -2.000 | 90,76 | -181.520,00 | -21,8% | |
| 2026-03-16 | Quan Joanne | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -7.287 | 91,98 | -670.242,96 | -80,5% | |
| 2026-03-16 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -7.287 | 91,98 | -670.242,96 | -80,5% | |
| 2026-03-16 | Radovich Peter | Officer, PRESIDENT AND COO | Open Market Sale | -16.515 | 91,98 | -1.519.015,02 | -182,4% | |
| 2026-02-13 | Ramasastry Saira | Director | Open Market Sale | -2.000 | 102,09 | -204.180,00 | -24,5% | |
| 2026-02-02 | Radovich Peter | Officer, PRESIDENT AND COO | Open Market Sale | -2.631 | 103,30 | -271.791,51 | -32,6% | |
| 2026-02-02 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -968 | 103,30 | -99.997,79 | -12,0% | |
| 2026-02-02 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -9.108 | 103,30 | -940.888,28 | -113,0% | |
| 2026-01-26 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.053 | 96,19 | -101.290,18 | -12,2% | |
| 2026-01-26 | Radovich Peter | Officer, PRESIDENT AND COO | Open Market Sale | -3.143 | 96,19 | -302.331,46 | -36,3% | |
| 2026-01-26 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -6.831 | 96,19 | -657.087,55 | -78,9% | |
| 2026-01-26 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -842 | 96,19 | -80.993,66 | -9,7% | |
| 2026-01-23 | Heron Patrick J | Director | Open Market Purchase | 131.425 | 68,48 | 8.999.984,00 | +1080,7% | |
| 2026-01-22 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.421 | 93,33 | -132.615,11 | -15,9% | |
| 2026-01-22 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7.098 | 93,33 | -662.422,27 | -79,5% | |
| 2026-01-22 | Radovich Peter | Officer, PRESIDENT AND COO | Open Market Sale | -2.382 | 93,33 | -222.300,63 | -26,7% | |
| 2026-01-22 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -926 | 93,33 | -86.419,14 | -10,4% | |
| 2026-01-22 | Quan Joanne | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1.822 | 93,33 | -170.038,51 | -20,4% | |
| 2026-01-20 | Quan Joanne | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -6.911 | 90,27 | -623.853,21 | -74,9% | |
| 2026-01-15 | Ramasastry Saira | Director | Open Market Sale | -2.000 | 90,99 | -181.980,00 | -21,9% | |
| 2025-12-22 | Ramasastry Saira | Director | Open Market Sale | -5.000 | 80,00 | -400.000,00 | -48,0% | |
| 2025-12-19 | GREY MICHAEL G | Director | Open Market Sale | -50.000 | 78,00 | -3.900.000,00 | -468,3% | |
| 2025-12-18 | Ramasastry Saira | Director | Open Market Sale | -1.000 | 70,00 | -70.000,00 | -8,4% | |
| 2025-12-18 | Ramasastry Saira | Director | Open Market Sale | -1.000 | 69,46 | -69.460,00 | -8,3% | |
| 2025-12-01 | GREY MICHAEL G | Director | Open Market Sale | -50.000 | 74,00 | -3.700.000,00 | -444,3% | |
| 2025-11-21 | GREY MICHAEL G | Director | Open Market Sale | -50.000 | 70,00 | -3.500.000,00 | -420,3% | |
| 2025-09-12 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -9.578 | 76,01 | -728.023,78 | -87,4% | |
| 2025-09-11 | Brege Laura | Director | Open Market Sale | -15.509 | 74,34 | -1.152.939,06 | -138,4% | |
| 2025-09-11 | Brege Laura | Director | Open Market Sale | -1.491 | 75,07 | -111.929,37 | -13,4% | |
| 2025-09-08 | Ramasastry Saira | Director | Open Market Sale | -17.000 | 0,00 | 0,00 | 0,0% | |
| 2025-08-11 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -8.000 | 0,00 | 0,00 | 0,0% | |
| 2025-08-11 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -40.000 | 62,00 | -2.480.000,00 | -297,8% | |
| 2025-08-07 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -10.000 | 58,00 | -580.000,00 | -69,6% | |
| 2025-08-07 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -40.000 | 55,25 | -2.210.040,00 | -265,4% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7.679.684 | 0 | 7.679.684 | 709.449.208 | Neu | +100,0% | |
| Janus Henderson Group Ltd. | 6.945.813 | 0 | 6.945.813 | 641.764.403 | Neu | +100,0% | |
| BlackRock, Inc. | 8.996.530 | 0 | 8.996.530 | 370.699.742 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.414.776 | 0 | 2.414.776 | 223.077.007 | Neu | +100,0% | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 70.000.000 | 0 | 70.000.000 | 209.440.280 | Neu | +100,0% | |
| FMR LLC | 8.520.375 | 0 | 8.520.375 | 201.108.375 | Neu | +100,0% | |
| STATE STREET CORP | 1.944.281 | 0 | 1.944.281 | 179.612.679 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 23.240.419 | 0 | 23.240.419 | 150.781.965 | Neu | +100,0% | |
| BVF INC/IL | 1.584.727 | 0 | 1.584.727 | 146.397.080 | Neu | +100,0% | |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 43.792.000 | 0 | 43.792.000 | 131.681.158 | Neu | +100,0% | |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.408.871 | 0 | 1.408.871 | 130.113.298 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 1.334.809 | 0 | 1.334.809 | 123.309.658 | Neu | +100,0% | |
| Novo Holdings A/S | 1.325.000 | 0 | 1.325.000 | 122.403.500 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.260.003 | 0 | 1.260.003 | 116.422.663 | Neu | +100,0% | |
| TANG CAPITAL MANAGEMENT LLC | 1.236.027 | 0 | 1.236.027 | 114.184.174 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1.063.548 | 0 | 1.063.548 | 98.250.564 | Neu | +100,0% | |
| TCG Crossover Management, LLC | 1.062.049 | 0 | 1.062.049 | 98.112.087 | Neu | +100,0% | |
| READYSTATE ASSET MANAGEMENT LP | 28.000.000 | 0 | 28.000.000 | 83.776.000 | Neu | +100,0% | |
| CAPSTONE INVESTMENT ADVISORS, LLC | 27.000.000 | 0 | 27.000.000 | 80.784.001 | Neu | +100,0% | |
| Rock Springs Capital Management LP | 811.294 | 0 | 811.294 | 74.947.340 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 2.590.804 | 0 | 2.590.804 | 71.646.601 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 774.841 | 0 | 774.841 | 71.579.812 | Neu | +100,0% | |
| Capital World Investors | 724.415 | 0 | 724.415 | 66.921.458 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 722.177 | 0 | 722.177 | 66.714.711 | Neu | +100,0% | |
| Polar Asset Management Partners Inc. | 21.375.000 | 0 | 21.375.000 | 63.845.394 | Neu | +100,0% | |
| Clearbridge Investments, LLC | 671.870 | 0 | 671.870 | 62.067.323 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 662.306 | 0 | 662.306 | 61.183.828 | Neu | +100,0% | |
| Point72 Asset Management, L.P. | 9.767.591 | 0 | 9.767.591 | 60.830.662 | Neu | +100,0% | |
| Paradigm Biocapital Advisors LP | 625.000 | 0 | 625.000 | 57.737.500 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 582.085 | 0 | 582.085 | 53.773.012 | Neu | +100,0% | |
| Woodline Partners LP | 567.894 | 0 | 567.894 | 52.462.048 | Neu | +100,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 539.031 | 0 | 539.031 | 49.795.684 | Neu | +100,0% | |
| MORGAN STANLEY | 724.566 | 0 | 724.566 | 49.055.884 | Neu | +100,0% | |
| FEDERATED HERMES, INC. | 506.211 | 0 | 506.211 | 46.763.773 | Neu | +100,0% | |
| UBS Group AG | 585.664 | 0 | 585.664 | 45.997.925 | Neu | +100,0% | |
| Connor, Clark & Lunn Investment Management Ltd. | 479.476 | 0 | 479.476 | 44.293.993 | Neu | +100,0% | |
| LOOMIS SAYLES & CO L P | 475.324 | 0 | 475.324 | 43.910.431 | Neu | +100,0% | |
| Nuveen, LLC | 474.227 | 0 | 474.227 | 43.809.090 | Neu | +100,0% | |
| Candriam S.C.A. | 464.216 | 0 | 464.216 | 42.884.274 | Neu | +100,0% | |
| BAKER BROS. ADVISORS LP | 445.975 | 0 | 445.975 | 41.199.171 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 427.090 | 0 | 427.090 | 39.454.574 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 423.511 | 0 | 423.511 | 39.123.946 | Neu | +100,0% | |
| BOONE CAPITAL MANAGEMENT LLC | 421.236 | 0 | 421.236 | 38.913.782 | Neu | +100,0% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 405.321 | 0 | 405.321 | 37.444.000 | Neu | +100,0% | |
| First Turn Management, LLC | 400.464 | 0 | 400.464 | 36.994.864 | Neu | +100,0% | |
| Soleus Capital Management, L.P. | 400.306 | 0 | 400.306 | 36.980.268 | Neu | +100,0% | |
| EMERALD ADVISERS, LLC | 397.263 | 0 | 397.263 | 36.699.156 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 394.920 | 0 | 394.920 | 36.482.710 | Neu | +100,0% | |
| Aequim Alternative Investments LP | 12.000.000 | 0 | 12.000.000 | 35.904.000 | Neu | +100,0% | |
| NEXT CENTURY GROWTH INVESTORS LLC | 385.539 | 0 | 385.539 | 35.616.092 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| NAN FUNG TRINITY (HK) Ltd | 232.679 | 232.679 | 0,0% | 27.239.731 | 19,49 | 100 % | 5 Q |
| Erste Asset Management GmbH | 205.000 | 210.000 | -2,4% | 25.215.000 | 18,05 | 100 % | 12 Q |
| Highlander Partners, L.P. | 122.980 | 122.980 | 0,0% | 14.397.269 | 10,30 | 0 % | 17 Q |
| Capricorn Fund Managers Ltd | 101.240 | 0 | +100,0% | 11.852.167 | 8,48 | 100 % | 1 Q |
| Atle Fund Management AB | 100.807 | 195.768 | -48,5% | 11.801.475 | 8,45 | 100 % | 10 Q |
| PEREGRINE CAPITAL MANAGEMENT LLC | 88.820 | 0 | +100,0% | 10.398.157 | 7,44 | 37 % | 1 Q |
| MACKAY SHIELDS LLC | 1.947.000 | 23.054.000 | -91,6% | 7.199.153 | 5,15 | 1 % | 9 Q |
| Secure Asset Management, LLC | 47.105 | 43.646 | +7,9% | 5.514.524 | 3,95 | 6 % | 15 Q |
| Hennion & Walsh Asset Management, Inc. | 37.492 | 93.592 | -59,9% | 4.389.188 | 3,14 | 100 % | 13 Q |
| OAK RIDGE INVESTMENTS LLC | 22.408 | 17.513 | +28,0% | 2.623.305 | 1,88 | 88 % | 5 Q |
| Diversified Trust Co | 19.050 | 10.745 | +77,3% | 2.230.183 | 1,60 | 0 % | 2 Q |
| SBI Okasan Asset Management Co.Ltd. | 14.200 | 14.200 | 0,0% | 1.746.600 | 1,25 | 100 % | 3 Q |
| Police & Firemen's Retirement System of New Jersey | 14.006 | 11.125 | +25,9% | 1.639.682 | 1,17 | 100 % | 7 Q |
| Ellsworth Advisors, LLC | 10.728 | 10.629 | +0,9% | 1.298.088 | 0,93 | 0 % | 2 Q |
| TOTH FINANCIAL ADVISORY CORP | 10.285 | 0 | +100,0% | 1.204.065 | 0,86 | 0 % | 1 Q |
| China Universal Asset Management Co., Ltd. | 9.705 | 10.708 | -9,4% | 1.136.164 | 0,81 | 100 % | 16 Q |
| Values First Advisors, Inc. | 5.912 | 9.397 | -37,1% | 1.109.704 | 0,79 | 0 % | 13 Q |
| AMI ASSET MANAGEMENT CORP | 8.532 | 8.859 | -3,7% | 998.841 | 0,71 | 100 % | 2 Q |
| Mirae Asset Global Investments Co., Ltd. | 7.978 | 10.243 | -22,1% | 933.984 | 0,67 | 100 % | 15 Q |
| NorthCrest Asset Manangement, LLC | 5.414 | 5.381 | +0,6% | 691.368 | 0,49 | 0 % | 3 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 60 | 3,3 | 140 |
| 31.03.2026 | ✓ | 328 | 381,9 | 7.780 |
| 31.12.2025 | ✓ | 301 | 377,4 | 5.464 |
| 30.09.2025 | ✓ | 288 | 390,1 | 4.900 |
| 30.06.2025 | ✓ | 230 | 357,5 | 3.224 |
| 31.03.2025 | ✓ | 230 | 370,0 | 2.926 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| Capital World Investors | 724.415 | 66.921.458 |
| Paradigm Biocapital Advisors LP | 625.000 | 57.737.500 |
| BAKER BROS. ADVISORS LP | 445.975 | 41.199.171 |
| Octagon Capital Advisors LP | 338.900 | 31.307.582 |
| RA CAPITAL MANAGEMENT, L.P. | 318.554 | 29.428.019 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 286.406 | 26.458.186 |
| PANAGORA ASSET MANAGEMENT INC | 129.114 | 11.927.551 |
| Neuberger Berman Group LLC | 80.549 | 7.441.116 |
| Lisanti Capital Growth, LLC | 39.005 | 3.603.282 |
| Cinctive Capital Management LP | 38.518 | 3.558.293 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| TENOR CAPITAL MANAGEMENT Co., L.P. | 43.792.000 | 15.216.000 | +53.2 % | 131.681.158 |
| Aequim Alternative Investments LP | 12.000.000 | 6.000.000 | +100.0 % | 35.904.000 |
| CAPSTONE INVESTMENT ADVISORS, LLC | 27.000.000 | 3.000.000 | +12.5 % | 80.784.001 |
| FMR LLC | 8.520.375 | 1.818.909 | +27.1 % | 201.108.375 |
| BlackRock, Inc. | 8.996.530 | 1.326.244 | +17.3 % | 370.699.742 |
| TCG Crossover Management, LLC | 1.062.049 | 1.000.000 | +1611.6 % | 98.112.087 |
| Frazier Life Sciences Management, L.P. | 7.679.684 | 884.563 | +13.0 % | 709.449.208 |
| Janus Henderson Group Ltd. | 6.945.813 | 880.505 | +14.5 % | 641.764.403 |
| TWO SIGMA INVESTMENTS, LP | 774.841 | 386.299 | +99.4 % | 71.579.812 |
| LAZARD ASSET MANAGEMENT LLC | 11.830.981 | 377.000 | +3.3 % | 536.929 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | 1.052.048 | -18.219.172 | -94.5 % | 97.188.194 |
| BNP PARIBAS FINANCIAL MARKETS | 23.240.419 | -6.647.359 | -22.2 % | 150.781.965 |
| MACKAY SHIELDS LLC | 23.054.000 | -2.478.000 | -9.7 % | 68.958.198 |
| READYSTATE ASSET MANAGEMENT LP | 28.000.000 | -2.414.000 | -7.9 % | 83.776.000 |
| SSI INVESTMENT MANAGEMENT LLC | 3.255.000 | -863.000 | -21.0 % | 9.706.410 |
| D. E. Shaw & Co., Inc. | 167.489 | -780.672 | -82.3 % | 15.472.634 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.408.871 | -684.711 | -32.7 % | 130.113.298 |
| Polar Capital Holdings Plc | 283.484 | -510.158 | -64.3 % | 26.188.252 |
| BARCLAYS PLC | 19.532 | -495.612 | -96.2 % | 1.804.367 |
| Nicholas Investment Partners, LP | 2.081.303 | -382.088 | -15.5 % | 17.944.671 |
Zusätzlich aktuell von 193 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck | Δ-Balken |
|---|---|---|---|---|---|---|---|
| 27.04.2026 | BlackRock, Inc. | Passiv (13G/A) | 5,70 % | 3.465.559 | Neu | – | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -5,31 pp | – | |
| 17.02.2026 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 11,80 % | 6.065.308 | +1,20 pp | – | |
| 13.02.2026 | Eventide Asset Management, LLC (+2) | Passiv (13G/A) | 4,10 % | 2.093.582 | -1,33 pp | – | |
| 27.01.2026 | Patrick J. Heron | Aktivist (13D/A) | 6,80 % | 4.108.404 | -0,80 pp | Item 4 is hereby amended and restated in its entirety to read as follows: Each of FLS I… | |
| 27.01.2026 | Frazier Life Sciences IX, L.P. (+2) | Aktivist (13D/A) | 5,90 % | 3.566.912 | -1,20 pp | Item 4 is hereby amended and restated in its entirety to read as follows: Each of FLS I… | |
| 27.01.2026 | James N. Topper | Aktivist (13D/A) | 6,70 % | 4.025.922 | -0,70 pp | Item 4 is hereby amended and restated in its entirety to read as follows: Each of FLS I… | |
| 27.01.2026 | Frazier Life Sciences X, L.P. (+2) | Aktivist (13D/A) | 0,80 % | 459.010 | +0,50 pp | Item 4 is hereby amended and restated in its entirety to read as follows: Each of FLS I… | |
| 27.01.2026 | Frazier Life Sciences XII, L.P. (+2) | Aktivist (13D/A) | 0,10 % | 62.931 | Neu | Item 4 is hereby amended and restated in its entirety to read as follows: Each of FLS I… | |
| 27.01.2026 | Frazier Life Sciences Public Fund, L.P. (+2) | Aktivist (13D/A) | 4,20 % | 2.514.947 | -0,80 pp | Item 4 is hereby amended and restated in its entirety to read as follows: Each of FLS I… | |
| 27.01.2026 | Frazier Life Sciences XI, L.P. (+2) | Aktivist (13D/A) | 1,80 % | 1.075.884 | +0,70 pp | Item 4 is hereby amended and restated in its entirety to read as follows: Each of FLS I… | |
| 05.12.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 10,60 % | 5.445.039 | +0,60 pp | – | |
| 14.11.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 10,00 % | 4.997.586 | -0,60 pp | – | |
| 14.11.2025 | BIOTECHNOLOGY VALUE FUND L P (+1) | Passiv (13G/A) | 1,50 % | 772.595 | Neu | – | |
| 14.11.2025 | BIOTECHNOLOGY VALUE FUND II LP (+1) | Passiv (13G/A) | 1,20 % | 610.666 | Neu | – | |
| 14.11.2025 | BVF PARTNERS L P/IL (+2) | Passiv (13G/A) | 3,00 % | 1.495.290 | Neu | – | |
| 14.11.2025 | Biotechnology Value Trading Fund OS LP (+1) | Passiv (13G/A) | 0,20 % | 82.238 | -0,80 pp | – | |
| 14.11.2025 | BVF GP HOLDINGS LLC | Passiv (13G/A) | 2,80 % | 1.383.261 | Neu | – | |
| 04.11.2025 | Patrick J. Heron | Aktivist (13D/A) | 7,60 % | 3.735.220 | 0,00 pp | Item 4 is hereby amended to remove references to "FLSPOF" and the "FLSPOF Shares" from t… | |
| 04.11.2025 | Frazier Life Sciences X, L.P. (+2) | Aktivist (13D/A) | 0,30 % | 168.308 | 0,00 pp | Item 4 is hereby amended to remove references to "FLSPOF" and the "FLSPOF Shares" from t… | |
| 04.11.2025 | Frazier Life Sciences XI, L.P. (+2) | Aktivist (13D/A) | 1,10 % | 544.954 | 0,00 pp | Item 4 is hereby amended to remove references to "FLSPOF" and the "FLSPOF Shares" from t… | |
| 04.11.2025 | James N. Topper | Aktivist (13D/A) | 7,40 % | 3.735.220 | 0,00 pp | Item 4 is hereby amended to remove references to "FLSPOF" and the "FLSPOF Shares" from t… | |
| 04.11.2025 | Frazier Life Sciences IX, L.P. (+2) | Aktivist (13D/A) | 7,10 % | 3.566.912 | 0,00 pp | Item 4 is hereby amended to remove references to "FLSPOF" and the "FLSPOF Shares" from t… | |
| 04.11.2025 | Frazier Life Sciences Public Fund, L.P. (+2) | Aktivist (13D/A) | 5,00 % | 2.514.947 | +1,90 pp | Item 4 is hereby amended to remove references to "FLSPOF" and the "FLSPOF Shares" from t… | |
| 20.08.2025 | Frazier Life Sciences X, L.P. (+2) | Aktivist (13D/A) | 0,30 % | 168.308 | 0,00 pp | – | |
| 20.08.2025 | Frazier Life Sciences IX, L.P. (+2) | Aktivist (13D/A) | 7,10 % | 3.566.912 | -0,60 pp | – | |
| 20.08.2025 | Frazier Life Sciences XI, L.P. (+2) | Aktivist (13D/A) | 1,10 % | 544.954 | +0,10 pp | – | |
| 20.08.2025 | Daniel Estes (+2) | Aktivist (13D/A) | Ausstieg | 0 | Neu | – | |
| 20.08.2025 | Frazier Life Sciences Public Overage Fund, L.P. (+2) | Aktivist (13D/A) | 1,90 % | 940.573 | +0,20 pp | – | |
| 20.08.2025 | Patrick J. Heron | Aktivist (13D/A) | 7,60 % | 3.735.220 | -5,80 pp | – | |
| 20.08.2025 | James N. Topper | Aktivist (13D/A) | 7,40 % | 3.735.220 | -5,90 pp | – | |
| 20.08.2025 | Frazier Life Sciences Public Fund, L.P. (+2) | Aktivist (13D/A) | 3,10 % | 1.574.374 | +0,50 pp | – | |
| 14.08.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 10,60 % | 5.236.277 | +0,30 pp | – | |
| 06.06.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 10,30 % | 5.081.957 | +0,60 pp | – | |
| 15.05.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 9,70 % | 4.775.375 | -4,60 pp | – | |
| 14.05.2025 | Janus Henderson Biotech Innovation Master Fund Ltd | Passiv (13G/A) | 12,70 % | 20.126.582 | +2,60 pp | – | |
| 14.05.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 14,30 % | 22.735.121 | +4,20 pp | – | |
| 07.05.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 10,10 % | 4.998.777 | +0,60 pp | – | |
| 14.02.2025 | Eventide Asset Management, LLC (+2) | Passiv (13G/A) | 5,43 % | 2.606.938 | +1,97 pp | – | |
| 14.02.2025 | Eventide Asset Management, LLC (+2) | Passiv (13G/A) | 3,46 % | 2.220.000 | -3,76 pp | – |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -790.155.000 $ | -13,43 $ | 890.916.000 $ | 242.494.000 $ |
| 2025-12-31 | 10-K | – | -23.363.000 $ | -0,47 $ | 842.813.000 $ | 314.690.000 $ |
| 2025-09-30 | 10-Q | – | 2.905.000 $ | 0,05 $ | 785.115.000 $ | 292.046.000 $ |
| 2025-06-30 | 10-Q | – | -5.861.000 $ | -0,12 $ | 725.825.000 $ | 255.158.000 $ |
| 2025-03-31 | 10-Q | – | -14.677.000 $ | -0,30 $ | 690.245.000 $ | 233.256.000 $ |
| 2024-12-31 | 10-K | – | -87.942.000 $ | -1,85 $ | 670.754.000 $ | 225.640.000 $ |
| 2024-09-30 | 10-Q | – | -14.235.000 $ | -0,30 $ | 667.893.000 $ | 232.024.000 $ |
| 2024-06-30 | 10-Q | – | -24.638.000 $ | -0,52 $ | 660.754.000 $ | 228.988.000 $ |
| 2024-03-31 | 10-Q | – | -25.279.000 $ | -0,54 $ | 651.962.000 $ | 234.603.000 $ |
| 2023-12-31 | 10-K | – | -163.415.000 $ | -4,00 $ | 646.621.000 $ | 248.670.000 $ |
| 2023-09-30 | 10-Q | – | -23.588.000 $ | -0,57 $ | 650.642.000 $ | 269.081.000 $ |
| 2023-06-30 | 10-Q | – | -74.038.000 $ | -1,94 $ | 443.588.000 $ | 78.610.000 $ |
| 2023-03-31 | 10-Q | – | -30.130.000 $ | -0,80 $ | 333.530.000 $ | 141.150.000 $ |
| 2022-12-31 | 10-K | – | -135.665.000 $ | -4,02 $ | 352.906.000 $ | 142.037.000 $ |
| 2022-09-30 | 10-Q | – | -35.706.000 $ | -1,02 $ | 364.347.000 $ | 169.297.000 $ |
| 2022-06-30 | 10-Q | – | -26.922.000 $ | -0,84 $ | 297.233.000 $ | 110.687.000 $ |
| 2022-03-31 | 10-Q | – | -36.606.000 $ | -1,17 $ | 278.148.000 $ | 108.932.000 $ |
| 2021-12-31 | 10-K | 19.138.000 $ | -83.988.000 $ | -2,77 $ | 294.651.000 $ | 120.212.000 $ |
| 2021-09-30 | 10-Q | – | -47.108.000 $ | -1,55 $ | 235.167.000 $ | 56.396.000 $ |
| 2021-06-30 | 10-Q | – | -43.894.000 $ | -1,45 $ | 247.668.000 $ | 95.737.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 521,3 Mio. | 336,4 Mio. | 178,9 Mio. | 75,1 Mio. | 3,1 Mio. | 100,0 % | +55,0% | |
| Livmarli | 360,0 Mio. | 213,3 Mio. | 141,8 Mio. | – | – | 69,1 % | +68,8% | |
| Bile Acid Medicines | 161,3 Mio. | 123,1 Mio. | 37,1 Mio. | – | – | 30,9 % | +31,0% | |
| License And Other Revenue | – | 479.000 | – | – | – | – | – | |
| License | – | – | 7,5 Mio. | 2,0 Mio. | 16,0 Mio. | – | – | |
| License Revenue | – | – | 7,5 Mio. | – | – | – | – |
Quartalsverlauf
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Product | 133,0 Mio. | 127,8 Mio. | 111,6 Mio. | 90,3 Mio. | 77,8 Mio. | 68,9 Mio. | 100,0 % | +47,3% | |
| Livmarli | 92,2 Mio. | 88,2 Mio. | 73,2 Mio. | 59,1 Mio. | 47,2 Mio. | 42,8 Mio. | 69,3 % | +56,0% | |
| Bile Acid Medicines | 40,8 Mio. | 39,6 Mio. | 38,4 Mio. | 31,2 Mio. | 30,5 Mio. | 26,1 Mio. | 30,7 % | +30,8% | |
| License And Other Revenue | – | – | – | 75.000 | 115.000 | 305.000 | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 06.05.2026 | 159,9 Mio. USD | -13,43 |
| Q3 2025 | 30.09.2025 | 04.11.2025 | 133,0 Mio. USD | 0,05 |
| Q2 2025 | 30.06.2025 | 06.08.2025 | 127,8 Mio. USD | -0,12 |
| Q1 2025 | 31.03.2025 | 07.05.2025 | 111,6 Mio. USD | -0,30 |
| Q3 2024 | 30.09.2024 | 12.11.2024 | 90,4 Mio. USD | -0,30 |
| Q2 2024 | 30.06.2024 | 07.08.2024 | 77,9 Mio. USD | -0,52 |
| Q1 2024 | 31.03.2024 | 08.05.2024 | 69,2 Mio. USD | -0,54 |
| Q3 2023 | 30.09.2023 | 02.11.2023 | 47,7 Mio. USD | -0,57 |
| Q2 2023 | 30.06.2023 | 07.08.2023 | 37,5 Mio. USD | -1,94 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 06.05.2026 | 10-Q | 31.03.2026 | 36 Tage | SEC » |
| 25.02.2026 | 10-K | 31.12.2025 | 56 Tage | SEC » |
| 04.11.2025 | 10-Q | 30.09.2025 | 35 Tage | SEC » |
| 06.08.2025 | 10-Q | 30.06.2025 | 37 Tage | SEC » |
| 07.05.2025 | 10-Q | 31.03.2025 | 37 Tage | SEC » |
| 26.02.2025 | 10-K | 31.12.2024 | 57 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 07.08.2024 | 10-Q | 30.06.2024 | 38 Tage | SEC » |
| 08.05.2024 | 10-Q | 31.03.2024 | 38 Tage | SEC » |
| 15.03.2024 | 10-K | 31.12.2023 | 75 Tage | SEC » |
| 02.11.2023 | 10-Q | 30.09.2023 | 33 Tage | SEC » |
| 07.08.2023 | 10-Q | 30.06.2023 | 38 Tage | SEC » |
| 04.05.2023 | 10-Q | 31.03.2023 | 34 Tage | SEC » |
| 08.03.2023 | 10-K | 31.12.2022 | 67 Tage | SEC » |
| 09.11.2022 | 10-Q | 30.09.2022 | 40 Tage | SEC » |
| 04.08.2022 | 10-Q | 30.06.2022 | 35 Tage | SEC » |
| 05.05.2022 | 10-Q | 31.03.2022 | 35 Tage | SEC » |
| 09.03.2022 | 10-K | 31.12.2021 | 68 Tage | SEC » |
| 15.11.2021 | 10-Q | 30.09.2021 | 46 Tage | SEC » |
| 05.08.2021 | 10-Q | 30.06.2021 | 36 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 09.03.2021 | 10-K | 31.12.2020 | 68 Tage | SEC » |
| 12.11.2020 | 10-Q | 30.09.2020 | 43 Tage | SEC » |
| 06.08.2020 | 10-Q | 30.06.2020 | 37 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 02.11.2023 | Kapitalerhöhung | $200,0 Mio | SEC » |
| 10.08.2022 | Kapitalerhöhung | $8,0 Mio · $23,00/Aktie | SEC » |
| 09.08.2022 | Kapitalerhöhung | $80,0 Mio · $28,35/Aktie | SEC » |
| 15.12.2020 | Kapitalerhöhung | $75,0 Mio · $20,00/Aktie | SEC » |
| 14.12.2020 | Kapitalerhöhung | $190,9 Mio · $25,45/Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 23.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 23.04.2026 | HV-Einladung | 15.06.2026 Jahres-HV | 20.04.2026 | DEF 14A | SEC » |
| 14.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 14.04.2025 | HV-Einladung | 29.05.2025 Jahres-HV | 03.04.2025 | DEF 14A | SEC » |
| 23.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 23.04.2024 | HV-Einladung | 05.06.2024 Jahres-HV | 10.04.2024 | DEF 14A | SEC » |
| 01.05.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 01.05.2023 | HV-Einladung | 12.06.2023 Jahres-HV | 17.04.2023 | DEF 14A | SEC » |
| 22.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 22.04.2022 | HV-Einladung | 02.06.2022 Jahres-HV | 08.04.2022 | DEF 14A | SEC » |
| 14.04.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 14.04.2021 | HV-Einladung | 04.06.2021 Jahres-HV | 07.04.2021 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Privatplatzierungen (Reg D)
Reg-D-Privatplatzierungen (Form D) der letzten sechs Jahre — SEC-befreite Kapitalaufnahmen ohne öffentliches Prospekt (z. B. PIPEs, Wandelanleihen an ausgewählte Investoren). Wiederholte Privatplatzierungen können auf laufenden Kapitalbedarf und Verwässerung der Altaktionäre hindeuten.
| Datum (US) | Art | Form | |
|---|---|---|---|
| 29.01.2026 | Privatplatzierung | D | SEC » |
| 30.12.2020 | Privatplatzierung | D | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Nur Metadaten — Emissions-Betrag und Investoren stehen im Dokument (SEC-Link).
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 09.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | reference. (e) The information provided in Item 5.02(b) of this Current Report on Form 8-K is incorporated by reference… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 18.05.2026 | Finanzierung/Anleihe | -0,15 | 65 | Mirum Pharmaceuticals gab Notes im Private Placement unter Regel 144A an qualifizierte institutionelle Käufer aus. Dies schuf eine neue Schu… 🔒 | SEC |
| 06.05.2026 | Quartalszahlen | 0,00 | 55 | Mirum Pharmaceuticals gab die Finanzergebnisse für das erste Quartal 2026 bekannt. | SEC |
| 25.02.2026 | Quartalszahlen | 0,00 | 50 | Mirum Pharmaceuticals veröffentlicht Finanzierungsergebnisse für Q4 und Gesamtjahr 2025 via Pressemitteilung vom 25. Februar 2026. | SEC |
| 26.01.2026 | Sonstiges | 0,00 | 5 | Regulation FD Disclosure (Item 7.01) mit Standardtext zur Haftungsausschluss-Regelung. Keine substantiven Unternehmensereignisse offengelegt… 🔒 | SEC |
| 12.01.2026 | Quartalszahlen | 0,00 | 65 | Mirum Pharmaceuticals kündigte am 12.01.2026 vorläufige Jahresergebnisse 2025 für die Produkte LIVMARLI, CHOLBAM und CTEXLI an und präsentie… 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 6.236 | 123,00 | 767.028 |
| 2026-06-29 | 15.591 | 123,77 | 1.929.698 |
| 2026-06-16 | 140 | 101,00 | 14.140 |
| 2026-06-12 | 8.012 | 99,54 | 797.514 |
| 2026-06-08 | 8.329 | 93,48 | 778.595 |
| 2026-06-03 | 70 | 92,17 | 6.452 |
| 2026-06-02 | 53 | 96,33 | 5.105 |
| 2026-05-27 | 50 | 98,90 | 4.945 |
| 2026-05-26 | 298 | 98,62 | 29.389 |
| 2026-05-15 | 13.235 | 111,39 | 1.474.247 |
| 2026-05-14 | 2 | 109,16 | 218 |
| 2026-05-13 | 34 | 106,88 | 3.634 |
| 2026-05-12 | 290 | 106,17 | 30.789 |
| 2026-05-11 | 286 | 107,16 | 30.648 |
| 2026-04-30 | 5.041 | 94,20 | 474.862 |
| 2026-04-28 | 1.450 | 92,48 | 134.096 |
| 2026-04-27 | 54 | 91,49 | 4.940 |
| 2026-04-17 | 5 | 95,86 | 479 |
| 2026-04-14 | 1 | 96,49 | 96 |
| 2026-04-10 | 1.788 | 98,95 | 176.923 |
| 2026-04-09 | 511 | 97,95 | 50.052 |
| 2026-04-08 | 8.831 | 95,65 | 844.685 |
| 2026-04-07 | 30 | 96,24 | 2.887 |
| 2026-04-06 | 1.515 | 94,17 | 142.668 |
| 2026-04-02 | 121 | 94,62 | 11.449 |
| 2026-03-31 | 54.876 | 87,90 | 4.823.600 |
| 2026-03-26 | 1 | 90,17 | 90 |
| 2026-03-24 | 714 | 89,43 | 63.853 |
| 2026-03-20 | 65 | 90,72 | 5.897 |
| 2026-03-18 | 4.097 | 96,55 | 395.565 |
| 2026-03-09 | 3.615 | 86,30 | 311.975 |
| 2026-03-05 | 3 | 93,04 | 279 |
| 2026-03-03 | 7.804 | 90,09 | 703.062 |
| 2026-03-02 | 973 | 92,29 | 89.798 |
| 2026-02-09 | 5.718 | 100,47 | 574.487 |